



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/077,577
		Filing Date	February 15, 2002
		First Named Inventor	SHACKLETON, CEDRIC
		Art Unit	1625
		Examiner Name	COLE, MONIQUE
Sheet 1 of 1	Attorney Docket Number	CHOR-003	

RECEIVED

AUG 04 2003

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ² -Number ² -Kind Code ² (if known)				

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
me		Li-Wei Guo, et al. "Synthesis of Ring B Unsaturated Estriols. Confirming the Structure of a Diagnostic Analyte for Smith-Lemli-Opitz Syndrome." (2001) Organic Letters. Vol. 3.	
me		Wassif-et-al., "Mutations in the Human Sterol Δ^7 -Reductase Gene at 11q12-13 Cause Smith-Lemli-Opitz Syndrome," Am. J. Hum. Genet. 63:55-62, 1998	

RECEIVED

AUG 13 2003


TC 1700

Examiner Signature	M. Cole	Date Considered	6/04
--------------------	---------	-----------------	------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Please type a plus sign (+) inside this box →



#4

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete If Known			
		Application Number	10/077,577		
		Filing Date	February 15, 2002		
		First Named Inventor	Cedric Shackleton		
		Group Art Unit	Unassigned		
		Examiner Name	Unassigned		
Sheet	1	of	4	Attorney Docket Number	CHOR-003

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials ¹	Cite No. ¹	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
MC			WO 01/92893		Schroepfer, et al.	12-06-01		

+

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), <small>publisher, city and/or country where published</small>	T ²
MC	-	ABUELO, et al. "Prenatal detection of the cholesterol biosynthetic defect in the Smith-Lemli-Opitz syndrome by the analysis of amniotic fluid sterols", <i>Am J Med Genet.</i> (1995) Vol. 56: 281-285.	
	-	ANDERSSON, et al. "Adrenal insufficiency in Smith-Lemli-Opitz Syndrome", <i>Am. J. Med Genet.</i> (1999) Vol. 82 (5): 382-384.	
	-	BRADLEY, et al. "Levels of unconjugated estriol and other maternal serum markers in pregnancies with Smith-Lemli-Opitz (RSH) syndrome fetuses", <i>Am J Med Genet.</i> (1999) Vol. 82: 355-358.	
	-	CLAYTON. "Disorders of cholesterol biosynthesis", <i>Arch. Dis. Child.</i> (1998) Vol. 78: 185-189.	
	-	DALLAIRE, et al. "Prenatal diagnosis of Smith-Lemli-Opitz syndrome is possible by measurement of 7-dehydrocholesterol in amniotic fluid", <i>Prenat. Diagn.</i> , (1995) Vol. 15: 855-858.	
MC	-	DONNAI, et al. "The lethal multiple congenital anomaly syndrome of polydactyly, sex reversal, renal hypoplasia, and unilobular lungs", <i>J. Med. Genet.</i> (1986) Vol. 23: 64-71.	


Examiner Signature	<i>Mc</i>	Date Considered	6/04
-----------------------	-----------	--------------------	------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/077.577
		Filing Date	February 15, 2002
		First Named Inventor	Cedric Shackleton
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet 2 of 4	Attorney Docket Number	CHOR-003	

+

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
Me		FITZKY, et al. "Mutations in the delta-7-sterol reductase gene in patients with the Smith-Lemli-Opitz syndrome", <i>Proc. Natl. Acad. Sci. USA</i> , (1998) Vol. 95: 8181-8186.	
		GLASS, et al. "Steroid sulphatase deficiency is the major cause of extremely low oestriol production at mid-pregnancy: A urinary steroid assay for the discrimination of steroid sulphatase deficiency from other causes", <i>Prenat. Diagn.</i> , (1998) Vol. 18: 789-800.	
		IRONS, et al. "Defective cholesterol biosynthesis in Smith-Lemli-Opitz syndrome", <i>Lancet</i> , (1993) Vol. 341: 1414.	
		IRONS, et al. "Prenatal diagnosis of Smith-Lemli-Opitz syndrome", <i>Prenat. Diagn.</i> , (1998) Vol. 18: 369-372.	
		KELLEY. "Inborn errors of cholesterol biosynthesis", <i>Adv. Pediatr.</i> , (2000) Vol. 47: 1-53.	
		KRATZ, et al. "Prenatal diagnosis of the RSH/ Smith-Lemli-Opitz syndrome", <i>Am. J. Med. Genet.</i> Vol. 82: 376-381 (1999).	
		MCGAUGHRAN, et al. "Prenatal diagnosis of Smith-Lemli-Opitz syndrome", <i>Am. J. Med. Genet.</i> , (1995) Vol. 56: 269-271.	
		MCKEEVER, et al. "Smith-Lemli-Opitz syndrome II: A disorder of the fetal adrenals?", <i>J. Med. Genet.</i> , (1990) Vol. 27: 465-466.	
		MILLS, et al. "First trimester prenatal diagnosis of Smith-Lemli-Opitz syndrome (7-dehydrocholesterol) reductase deficiency", <i>Pediatr. Res.</i> , (1996) Vol. 39: 816-819.	
		MOEBIUS, et al. "Molecular cloning and expression of the human delta 7-sterol reductase", <i>Proc. Natl. Acad. Sci. USA</i> , (1998) Vol. 95: 1899-1902.	
MC		PALOMAKI, et al. "Maternal serum screening for Down syndrome in the United States: A 1995 survey", <i>Am. J. Med. Genet.</i> , (1997) Vol. 176: 1046-1051.	


Examiner Signature	M. Cole	Date Considered	6/04
--------------------	---------	-----------------	------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Complete if Known	
				Application Number	10/077.577
		Filing Date	February 15, 2002		
		First Named Inventor	Cedric Shackleton		
		Group Art Unit	Unassigned		
		Examiner Name	Unassigned		
Sheet	3	CHOR-003	4	Attorney Docket Number	CHOR-003

+

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
MC		ROSSITER, et al. "Smith-Lemli-Opitz Syndrome: Prenatal diagnosis by quantification of cholesterol precursors in amniotic fluid", <i>American Journal of Medical Genetics</i> , (1995) Vol. 56: 272-275.	
		SHACKLETON. "Mass spectrometry in the diagnosis of steroid-related disorders and in hypertension research", <i>J. Steroid Biochem. Molec. Biol.</i> , (1993) Vol. 45: 127-140.	
		SHACKLETON, et al. "Equine type estrogens produced by a pregnant woman carrying a Smith-Lemli-Opitz syndrome fetus", <i>J. Clin. Endocrinol. Metab.</i> , (1999) Vol. 84: 1157-1159.	
		SHACKLETON, et al. "Midgestational maternal urine steroid markers of fetal Smith-Lemli-Opitz syndrome (7-dehydrocholesterol 7-reductase deficiency)", <i>Steroids</i> , (1999) Vol. 64: 446-452.	
		SHACKLETON, et al. "Neonatal urinary steroids in Smith-Lemli-Opitz Syndrome associated with 7-dehydrocholesterol reductase deficiency", <i>Steroids</i> , (1999) Vol. 64: 481-490.	
		SHACKLETON, et al. "Dehydro-oestriol and dehydropregnanetriol are candidate analytes for prenatal diagnosis of Smith-Lemli-Opitz syndrome", <i>Prenat. Diagn.</i> , (2001) Vol. 21: 207-212.	
		SHARP, et al. "First-trimester diagnosis of Smith-Lemli-Opitz syndrome", <i>Prenat. Diagn.</i> , (1997) Vol. 17(4): 355-361.	
		SMITH, et al. "A newly recognized syndrome of congenital anomalies", <i>J. Pediat.</i> , (1964) Vol. 64: 210-221.	
		STEINER, et al. "Smith-Lemli-Opitz syndrome", <i>eMedicine J.</i> , (April 4, 2001) Vol. 2(4).	
		STEINER, et al. "Smith-Lemli-Opitz syndrome", <i>eMedicine J.</i> , (February 5, 2002) Vol. 3(2).	
MC		TINT, et al. "Defective cholesterol biosynthesis associated with the Smith-Lemli-Opitz syndrome", <i>N. Engl. J. Med.</i> , (1994) Vol. 330: 107-113.	

Examiner Signature	<i>M. Cole</i>	Date Considered	<i>6/04</i>
---------------------------	----------------	------------------------	-------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/077.577
		Filing Date	February 15, 2002
		First Named Inventor	Cedric Shackleton
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
		Attorney Docket Number	CHOR-003
Sheet	4	Of	4

+

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
MC		TINT, et al. "Fetal Smith-Lemli-Opitz syndrome can be detected accurately and reliably by measuring amniotic fluid dehydrocholesterols", <i>Prenat. Diagn.</i> , (1998) Vol. 18: 651-658.	
MC		Waterham, et al. "Smith-Lemli-Opitz Syndrome is Cuased by Mutations in the 7-Dehydrocholesterol Reducatse Gene", <i>Am. J. Hum. Genet.</i> , (1998) Vol. 63: 329-338.	

Examiner Signature	<i>M. Cole</i>	Date Considered	6/04
-----------------------	----------------	--------------------	------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.